Bioretec Ltd在2026年3月27日前通过权利问题寻求5M-15M欧元,主要股东支持,股票稀释率高达12%。 Bioretec Ltd seeks €5M–15M via rights issue by March 27, 2026, with major shareholder backing and up to 12% share dilution.

Bioretec有限公司计划通过发行多达15亿股的新股份,解决权利问题,筹集500万至1 500万欧元,目的是加强其资产负债表和支持增长,需要股东在2026年3月27日前批准。 Bioretec Ltd plans a rights issue to raise €5 million to €15 million by issuing up to 1.5 billion new shares, aiming to strengthen its balance sheet and support growth, with shareholder approval needed by March 27, 2026. 最大的股东斯蒂芬工业公司(Stephen Industries Inc Oy)承诺投赞成票,并购买500万欧元的新股,包括承销任何未出售的股份。 The largest shareholder, Stephen Industries Inc Oy, has pledged to vote in favor and subscribe for up to €5 million in new shares, including underwriting any unsold portions. 2026年问题2中预期提供的这项产品须遵守监管和市场条件。 The offering, expected in Q2 2026, is subject to regulatory and market conditions. 该公司还寻求获得授权,为奖励、收购或金融实力额外发行多达2.5亿股的股份,潜在的股份稀释上限为12%。 The company also seeks authorization to issue up to 250 million additional shares for incentives, acquisitions, or financial strength, with potential share dilution capped at 12%. 该公告不准备在美国、加拿大、日本、澳大利亚或其他特定管辖区发布。 The announcement is not for release in the U.S., Canada, Japan, Australia, or other specified jurisdictions.